A recent pharmacokinetic study on Casperome, the Boswellia serrata extract formulated with Indena’s proprietary Phytosome technology, was found to offer increase absorption of major boswellic acids in human subjects.
 
Boswellic acids have long been considered the main bioactive components of Boswellia serrata, and many pre-clinical studies have confirmed their bioactivities. In particular, recent mechanistic studies have validated the capacity of the beta-boswellic acid family to modulate physiological response to various challenges, but preliminary pharmacokinetic studies in animals and humans have highlighted the poor oral absorption of boswellic acids.
 
To overcome this problem, Indena has formulated a purified mixture of boswellic acids from Boswellia serrata with lecithin, taking advantage of its proprietary Phytosome technology platform to optimize their absorption. In a previous pre-clinical work such superior absorption was demonstrated both at the plasma and at the tissue level.
 
The randomized, double blind, cross-over comparative pharmacokinetic study in healthy volunteers with a single oral dosage of 500 mg confirmed a marked increase of major boswellic acids in comparison with the unformulated extract. Plasma levels of most relevant boswellic acids measured after Casperome administration, in particular beta-boswellic acids, were in the range of expected biological activity, thus representing strong support for a rational dosage regimen in clinical testing.
 
Clinical investigations in four controlled studies have given further support to the relevance of this pharmacokinetic study.
 
Christian Artaria, marketing director of Indena, commented: “We are excited for the results we achieved, as for the first time, with a single dosage of 500 mg of
Casperome, relevant plasmatic levels could be reached and measured in humans.”
 
For more information: http://us.indena.com